ArticlePolymers2026
Biocomposite Microparticles Incorporating Ibuprofen and ZnO Nanoparticles for Controlled Drug Delivery and Antimicrobial Therapy.
Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Preparation of complex biomaterials capable of providing both controlled drug delivery and an increased antimicrobial effect without affecting healthy cells remains a major challenge in pharmaceutical and biomedical applications. This study reports the successful preparation of biocomposite microparticles based on carboxymethyl chitosan and poly (vinyl alcohol), co-loaded with zinc oxide nanoparticles with antimicrobial effect and Ibuprofen with anti-inflammatory, antipyretic, and analgesic effect. An environmentally friendly water-in-oil emulsion method using DL-limonene as a biocompatible oil phase was used to obtain these microparticles. FTIR analysis confirmed the formation of intermolecular ester and amide bonds and the successful incorporation of zinc oxide nanoparticles into the polymeric matrix. The obtained microparticles exhibited diameters ranging from 533 to 1054 nm and provided a biphasic Ibuprofen release profile, characterized by an initial burst release within the first 3 h followed by sustained diffusion-controlled release, achieving cumulative drug release of 84-100%. Biocomposite microparticles presented excellent hemocompatibility, with hemolysis values between 0.41% and 2.47%. Moreover, after 24 h of exposure to microparticles, human dermal fibroblasts exhibited a cellular viability ranging from 82.24% to 94.22% whereas prolonged treatment for 48 h resulted in a slight decrease of cell viability until 74.88%. Biocomposite microparticles exhibited notable antimicrobial activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.